Welcome to our dedicated page for Waystar Holding news (Ticker: WAY), a resource for investors and traders seeking the latest updates and insights on Waystar Holding stock.
Waystar Holding Corp. (Nasdaq: WAY) is a healthcare payment software company whose news flow centers on technology innovation, financial performance, and capital markets activity. As a provider of mission-critical, cloud-native software for healthcare payments, Waystar regularly issues updates about its AI capabilities, platform enhancements, and the impact of its solutions on revenue cycle operations for providers.
Readers of this news page can expect coverage of announcements related to Waystar AltitudeAI™, agentic intelligence, and the company’s broader vision for an autonomous revenue cycle. Recent communications have highlighted how Waystar’s AI-powered platform is used to prevent claim denials, accelerate denial appeals, improve reimbursement recovery, and reduce administrative workload across clinical documentation and billing workflows.
Waystar also reports quarterly and annual financial results, which are typically accompanied by earnings press releases and Form 8-K filings. These updates may include discussions of revenue trends, margins, key operating metrics, and guidance, as well as commentary from management on business performance. In addition, the company announces participation in investor conferences and presentations at major healthcare and technology events, reflecting its engagement with the investment community.
Corporate development and strategic transactions are another important theme in Waystar’s news. The company has announced the acquisition and integration of Iodine Software, describing how the combination of large clinical and financial datasets enhances its AI platform and expands its total addressable market. Index-related news, such as Waystar’s inclusion in the S&P SmallCap 600® Index, also appears in its releases.
For investors, analysts, and healthcare professionals, this news page provides a centralized view of Waystar’s product innovations, AI initiatives, financial disclosures, capital structure developments, and strategic milestones. Regular visits can help readers follow how the company’s software platform and data assets are evolving within the U.S. healthcare payment landscape.
Waystar (Nasdaq: WAY) was named an Inc. Best in Business honoree on Feb. 16, 2026, in the Best AI Implementation category for its AltitudeAI suite. According to the company, AltitudeAI has helped clients prevent $15.5 billion in denials, deliver 95% time savings in denial prevention workflows, and increase denial overturn rates by double digits.
The award highlights Waystar's AI embedded in revenue-cycle workflows and its proprietary data asset unifying financial, clinical, and administrative intelligence.
Waystar (Nasdaq: WAY) was named Best in KLAS for Patient Access on Feb 4, 2026, extending its decade-long streak. The company highlights AI-powered Waystar AltitudeAI and claims outcomes: hospitals face >$10B in payer authorization costs, 60% of denials stem from front-end issues,
and Waystar cites up to 55% reduction in eligibility denials, 90% auto-approval on prior authorizations, and up to 55% discovery rate for previously uninsured patients.
Waystar (Nasdaq: WAY) will report fourth-quarter and fiscal year 2025 results for the period ended December 31, 2025 before market open on February 17, 2026. The company will host a conference call at 8:30 a.m. ET and a live audio webcast will be available and archived on its investor site.
Waystar (NASDAQ: WAY) introduced agentic intelligence to its cloud-native revenue-cycle platform on January 12, 2026, extending Waystar AltitudeAI capabilities. The system leverages a proprietary data network from >7.5 billion annual transactions and coverage of one in three U.S. hospital discharges to automate workflows that act, learn, and execute tasks with minimal intervention. Early results cited include $15.5 billion in prevented denials, ~40% reduction in manual correction workload, and 95% time savings in denial-related workflows. Company will discuss strategy at the J.P. Morgan Healthcare Conference on January 12, 2026.
Waystar (NASDAQ: WAY) announced that CEO Matt Hawkins will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.
The company said it will provide a live webcast of the presentation on its Investor Relations site at https://investors.waystar.com/news-events/events, and that a recording will be available on the site after the event.
Waystar (Nasdaq: WAY) announced that CEO Matt Hawkins and CFO Steve Oreskovich will participate in three investor conferences in early December 2025. Mr. Oreskovich will hold one-on-one meetings at the Evercore ISI HealthCONx on Dec 2, 2025 and will appear in a fireside chat at Citi's Global Healthcare Conference on Dec 3, 2025 at 1:45 p.m. ET, plus one-on-one meetings. Mr. Hawkins will appear in a fireside chat at Barclays 23rd Annual Global Technology Conference on Dec 10, 2025 at 3:40 p.m. PT and will conduct one-on-one meetings. Waystar will webcast the Citi and Barclays fireside chats and post recordings on its Investor Relations website.
Waystar (Nasdaq: WAY) announced it will join the S&P SmallCap 600, effective before market open on September 22, 2025. The company highlighted recent operating strength including double-digit revenue growth over the past 15 months, $1.8 trillion in gross claims processed annually, 115% net revenue retention, and scaled clients up to 15% year-over-year.
Waystar cited product innovation such as AltitudeAI, which the company says accelerates denial appeals 3x faster and boosts overturn rates by 40%+. Membership in the index is expected to broaden the shareholder base, increase institutional visibility, and enhance trading liquidity.
Waystar (Nasdaq: WAY) reported Q3 2025 revenue $268.7M, up 12% YoY, GAAP net income of $30.6M (diluted GAAP EPS $0.17) and non‑GAAP net income of $67.8M (non‑GAAP EPS $0.37).
Adjusted EBITDA was $112.7M with a 42% margin; cash flow from operations was $82M and unlevered free cash flow $96M. Net revenue retention was 113% and clients with >$100k LTM revenue rose 11% to 1,306.
Waystar raised full‑year 2025 guidance to $1.085–$1.093B revenue, adjusted EBITDA $451–$455M, and non‑GAAP net income $271–$274M.
RIS Rx (WAY) appointed John Driscoll as Chairman of the Board effective October 15, 2025. Driscoll is a veteran healthcare executive with leadership roles across payers, providers, and health‑tech platforms, including Executive Vice President and President, U.S. Healthcare at Walgreens Boots Alliance, nearly a decade as CEO of CareCentrix, and earlier roles at Castlight Health and Medco. He currently serves as Independent Chairman at Waystar (Nasdaq: WAY) and chairs the boards of UConn Health and Magnit Global. Management says Driscoll’s experience in scaling care‑at‑home and healthcare payment technology will support RIS Rx’s expansion and efforts to ensure patient financial support reaches patients.
Waystar (Nasdaq: WAY) will report third-quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, October 29, 2025 after market close. The company will host a conference call at 4:30 p.m. Eastern Time the same day and provide a live audio webcast accessible from its investor relations website.
The webcast will be archived on the investor site for later access by investors and analysts.
FAQ
What is the current stock price of Waystar Holding (WAY)?
What is the market cap of Waystar Holding (WAY)?
